Accelerating DoD’s Fielding of Prototypes for Medical Countermeasures

New Opportunities

New RPP Released:
None at this time

New Draft RPPs Released:
Draft SOO: Small Molecule Therapeutics

New RFIs Released:
None at this time


Current Members




Funded to Date


Non-Traditional Members


Prophylaxis, pretreatment, and post-exposure prophylaxis


Systems and devices to identify CBRN agents and assist in making medical decisions


Therapeutics for post-exposure and post-symptomatic

The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.


Companies that are part of the US Industrial base, as well as new and emerging non-traditional defense contractors, are encouraged to join the MCDC and participate in Federally-funded R&D projects.

• Traditional Contractors
• Non-Traditionals (Companies that don’t typically participate in Federal R&D)
• Academia
• Non-Profit/ Not-For-Profit Research Institutions

Led by

MCDC Medical CBRN Defense Consortium Favicon

MCDC research and prototype work is executed by project teams from a broad-based industry/ academia collaboration.

Sponsored by

Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense

Managed by

Collaboration Management Firm Advanced Technology International (ATI)